Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Assets (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Non-Current Assets for 12 consecutive years, with $470.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 3.77% to $470.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 0.29% change, with the full-year FY2025 number at $470.5 million, up 3.77% from a year prior.
  • Non-Current Assets was $470.5 million for Q4 2025 at Iovance Biotherapeutics, down from $475.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $484.9 million in Q2 2025 to a low of $187.0 million in Q1 2023.
  • A 3-year average of $443.5 million and a median of $471.5 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 159.0% in 2024, then dropped 6.24% in 2025.
  • Iovance Biotherapeutics' Non-Current Assets stood at $472.5 million in 2023, then decreased by 4.04% to $453.4 million in 2024, then grew by 3.77% to $470.5 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Non-Current Assets are $470.5 million (Q4 2025), $475.9 million (Q3 2025), and $484.9 million (Q2 2025).